Clinical trial
A Multicenter, Randomized, Open-label, and Parallel Assignment Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in Combination With Metformin in the Treatment of Type 2 Diabetes
NCT05816057 is registered in ClinicalTrials.gov with Hangzhou Jiuyuan Gene Engineering Co. Ltd., as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Open-label, and Parallel Assignment Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in Combination With Metformin in the Treatment of Type 2 Diabetes
- Lead sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 25, 2022
- Completion date
- October 31, 2023
- Enrollment
- 476 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.